Consolidated revenue grows from ₹2,166.7 Cr to ₹2,545.0 Cr from Q1 FY26 to Q1 FY27 — steady top-line expansion across hospitals and diagnostics.

Average realization per patient rises from ₹878 to ₹952 from Q1 FY26 to Q1 FY27 — stronger pricing power and higher-value treatments.

Diagnostics operating margin expands from 23.0% to 23.9% from Q1 FY26 to Q1 FY27 — improved efficiency and a growing direct-to-consumer base.

High-performing hospital facilities grow from 11 to 14 from Q1 FY26 to Q1 FY27 — core assets scale effectively with stable occupancy.

Net debt to EBITDA improves from 0.92x to 1.01x from Q1 FY26 to Q1 FY27 — leverage remains manageable despite ongoing capital investments.

Operating expenses accelerate from ₹1,676.0 Cr to ₹2,007.9 Cr from Q1 FY26 to Q1 FY27 — cost inflation outpaces revenue growth.

Consolidated EBITDA margin contracts from 22.6% to 22.3% from Q1 FY26 to Q1 FY27 — margin compression from higher operational costs.

Cash reserves fall from ₹486 Cr to ₹347 Cr from Q1 FY26 to Q1 FY27 — tighter liquidity amid capex and debt servicing.

International payor share drops from 8.1% to 7.5% from Q2 FY26 to Q1 FY27 — weaker cross-border demand pressures revenue mix.

Hospital EBITDA margin declines from 22.6% to 20.6% from Q1 FY26 to Q1 FY27 — core operations face profit squeeze despite steady bed occupancy.